Trump’s Back, but DC’s Coming for Your Money!

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

James Hassard Biography and Net Worth

Chief Commercial Officer of Crinetics Pharmaceuticals

Jim Hassard has over thirty years of bio-pharmaceutical experience. Most recently, Jim Hassard was chief commercial officer at Arrowhead Pharmaceuticals, where he began building the company’s commercial capabilities and launch strategy for three rare disease programs.

Between 2016 and 2020, Mr. Hassard was senior vice president of marketing and market access at Coherus BioSciences, where he built the company’s commercial capabilities, including patient and provider services, in advance of their first FDA-approved specialty product. Earlier in his career, Mr. Hassard held several positions over a 17-year period at Amgen Inc., in therapeutic areas including oncology, nephrology and endocrinology. Among these, he was general manager of Amgen Portugal, and U.S. brand lead for Sensipar® (cinacalcet), expanding the FDA label into a rare-endocrinology indication. Mr. Hassard earned a Bachelor of Science in pharmacology from the University of Toronto, followed by a Master’s in Business Administration from Nova Southeastern University.

What is James Hassard's net worth?: The estimated net worth of James Hassard is at least $1.60 million as of July 5th, 2024. Mr. Hassard owns 29,259 shares of Crinetics Pharmaceuticals stock worth more than $1,601,052 as of November 17th. This net worth approximation does not reflect any other investments that Mr. Hassard may own. Additionally, Mr. Hassard receives a salary of $623,500.00 as Chief Commercial Officer at Crinetics Pharmaceuticals. Learn More about James Hassard's net worth.
How old is James Hassard?: Mr. Hassard is currently 58 years old. There are 4 older executives and no younger executives at Crinetics Pharmaceuticals. The oldest executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who is 61 years old. Learn More on James Hassard's age.
What is James Hassard's salary?: As the Chief Commercial Officer of Crinetics Pharmaceuticals, Inc., Mr. Hassard earns $623,500.00 per year. There are 5 executives that earn more than Mr. Hassard. The highest earning executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who commands a salary of $978,340.00 per year. Learn More on James Hassard's salary.
How do I contact James Hassard?: The corporate mailing address for Mr. Hassard and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on James Hassard's contact information.
Has James Hassard been buying or selling shares of Crinetics Pharmaceuticals?: James Hassard has not been actively trading shares of Crinetics Pharmaceuticals during the past quarter. Most recently, James Hassard sold 15,000 shares of the business's stock in a transaction on Friday, July 5th. The shares were sold at an average price of $44.08, for a transaction totalling $661,200.00. Following the completion of the sale, the insider now directly owns 29,259 shares of the company's stock, valued at $1,289,736.72. Learn More on James Hassard's trading history.
Who are Crinetics Pharmaceuticals' active insiders?: Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Richard Struthers (CEO), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Crinetics Pharmaceuticals?: During the last year, insiders at the sold shares 34 times. They sold a total of 560,048 shares worth more than $26,278,027.53. The most recent insider tranaction occured on October, 3rd when insider Dana Pizzuti sold 14,375 shares worth more than $785,306.25. Insiders at Crinetics Pharmaceuticals own 6.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.
Information on this page was last updated on 10/3/2024.

James Hassard Insider Trading History at Crinetics Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/5/2024	Sell	15,000	$44.08	$661,200.00	29,259
6/21/2024	Sell	15,000	$44.66	$669,900.00	29,259

James Hassard Buying and Selling Activity at Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $54.72

$54.42

$60.15

50 Day Range

MA: $54.97

$49.82

$60.69

2 Week Range

Now: $54.72

$27.55

$62.53

Volume

908,877 shs

Average Volume

635,371 shs

Market Capitalization

$5.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Trump’s Back, but DC’s Coming for Your Money!

From Genesis Gold Group | Ad

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

James Hassard Biography and Net Worth

What is James Hassard's net worth?

How old is James Hassard?

What is James Hassard's salary?

How do I contact James Hassard?

Has James Hassard been buying or selling shares of Crinetics Pharmaceuticals?

Who are Crinetics Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Crinetics Pharmaceuticals?